Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Interest & Investment Income (2023 - 2025)

CG Oncology filings provide 3 years of Interest & Investment Income readings, the most recent being $7.4 million for Q4 2025.

  • On a quarterly basis, Interest & Investment Income rose 19.2% to $7.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.9 million, a 12.42% increase, with the full-year FY2025 number at $29.9 million, up 12.42% from a year prior.
  • Interest & Investment Income hit $7.4 million in Q4 2025 for CG Oncology, roughly flat from $7.4 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $7.9 million in Q3 2024 to a low of $771000.0 in Q2 2023.
  • Median Interest & Investment Income over the past 3 years was $6.6 million (2024), compared with a mean of $5.3 million.
  • Biggest five-year swings in Interest & Investment Income: soared 800.52% in 2024 and later decreased 5.97% in 2025.
  • CG Oncology's Interest & Investment Income stood at $2.8 million in 2023, then soared by 122.72% to $6.2 million in 2024, then increased by 19.2% to $7.4 million in 2025.
  • The last three reported values for Interest & Investment Income were $7.4 million (Q4 2025), $7.4 million (Q3 2025), and $7.3 million (Q2 2025) per Business Quant data.